Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 202

1.

Skeletal and extraskeletal actions of denosumab.

Sinningen K, Tsourdi E, Rauner M, Rachner TD, Hamann C, Hofbauer LC.

Endocrine. 2012 Aug;42(1):52-62. doi: 10.1007/s12020-012-9696-x. Epub 2012 May 13. Review.

PMID:
22581255
2.

Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.

Dempster DW, Lambing CL, Kostenuik PJ, Grauer A.

Clin Ther. 2012 Mar;34(3):521-36. doi: 10.1016/j.clinthera.2012.02.002. Review.

PMID:
22440513
3.

Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology.

Hofbauer LC, Heufelder AE.

J Mol Med (Berl). 2001 Jun;79(5-6):243-53. Review.

PMID:
11485016
4.

Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.

Kostenuik PJ, Nguyen HQ, McCabe J, Warmington KS, Kurahara C, Sun N, Chen C, Li L, Cattley RC, Van G, Scully S, Elliott R, Grisanti M, Morony S, Tan HL, Asuncion F, Li X, Ominsky MS, Stolina M, Dwyer D, Dougall WC, Hawkins N, Boyle WJ, Simonet WS, Sullivan JK.

J Bone Miner Res. 2009 Feb;24(2):182-95. doi: 10.1359/jbmr.081112.

5.

[Control of bone resorption by RANKL-RANK system].

Harada S, Takahashi N.

Clin Calcium. 2011 Aug;21(8):1121-30. doi: CliCa110811211130. Review. Japanese.

PMID:
21814016
6.

[RANKL inhibition as therapy for joint damage].

Akama H.

Nihon Rinsho Meneki Gakkai Kaishi. 2007 Oct;30(5):404-7. Review. Japanese.

7.

Advances in bone biology and new treatments for bone loss.

Gallagher JC.

Maturitas. 2008 May 20;60(1):65-9. doi: 10.1016/j.maturitas.2008.04.005. Epub 2008 Jun 13. Review.

PMID:
18555623
8.

RANK ligand inhibition with denosumab for the management of osteoporosis.

Lewiecki EM.

Expert Opin Biol Ther. 2006 Oct;6(10):1041-50. Review.

PMID:
16989586
9.

Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss.

Trouvin AP, Goëb V.

Clin Interv Aging. 2010 Nov 19;5:345-54. doi: 10.2147/CIA.S10153. Review.

10.

RANKL inhibition for the management of patients with benign metabolic bone disorders.

Anastasilakis AD, Toulis KA, Polyzos SA, Terpos E.

Expert Opin Investig Drugs. 2009 Aug;18(8):1085-102. doi: 10.1517/13543780903048929. Review.

PMID:
19558335
11.

Inhibition of RANK/RANKL signal transduction pathway: a promising approach for osteoporosis treatment.

Bai YD, Yang FS, Xuan K, Bai YX, Wu BL.

Med Hypotheses. 2008 Aug;71(2):256-8. doi: 10.1016/j.mehy.2008.03.021. Epub 2008 Apr 28.

PMID:
18445511
12.

Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength.

Kostenuik PJ.

Curr Opin Pharmacol. 2005 Dec;5(6):618-25. Epub 2005 Sep 26. Review.

PMID:
16188502
13.

Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis.

Dougall WC.

Clin Cancer Res. 2012 Jan 15;18(2):326-35. doi: 10.1158/1078-0432.CCR-10-2507. Epub 2011 Oct 26.

14.

Osteoprotegerin and inflammation.

Saidenberg Kermanac'h N, Bessis N, Cohen-Solal M, De Vernejoul MC, Boissier MC.

Eur Cytokine Netw. 2002 Apr-Jun;13(2):144-53. Review.

15.
16.

[The role of rank-ligand inhibition in the treatment of postmenopausal osteoporosis].

Varenna M, Gatti D.

Reumatismo. 2010 Jul-Sep;62(3):163-71. Review. Italian.

17.

[Osteoporosis and RANKL signal].

Nakamura M, Udagawa N.

Clin Calcium. 2011 Aug;21(8):1149-55. doi: CliCa110811491155. Review. Japanese.

PMID:
21814019
18.

Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice.

Helas S, Goettsch C, Schoppet M, Zeitz U, Hempel U, Morawietz H, Kostenuik PJ, Erben RG, Hofbauer LC.

Am J Pathol. 2009 Aug;175(2):473-8. doi: 10.2353/ajpath.2009.080957. Epub 2009 Jul 9. Erratum in: Am J Pathol. 2009 Nov;175(5):2249.

19.
20.

Denosumab for bone diseases: translating bone biology into targeted therapy.

Tsourdi E, Rachner TD, Rauner M, Hamann C, Hofbauer LC.

Eur J Endocrinol. 2011 Dec;165(6):833-40. doi: 10.1530/EJE-11-0454. Epub 2011 Aug 18. Review. Erratum in: Eur J Endocrinol. 2012 Jan;166(1):137.

Supplemental Content

Support Center